FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894989588> ?p ?o ?g. }

• W2894989588 endingPage "576" @default.
• W2894989588 startingPage "569" @default.
• W2894989588 abstract "Objective: Brigatinib, ceritinib, and alectinib are approved to treat crizotinib-refractory anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC), but no trial has compared them head-to-head. A matching-adjusted indirect comparison (MAIC) was conducted to estimate the relative efficacy of these agents in the crizotinib-refractory setting.Methods: MAIC is a propensity score-type method that adjusts for differences in baseline characteristics between trials to estimate relative efficacy. Analyses were based on patient-level data from the ALTA trial for brigatinib and published summary-level trial data from ASCEND-1 and ASCEND-2 for ceritinib and NP28761 and NP28673 for alectinib. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared.Results: After matching, all key baseline characteristics were balanced between trials. Compared with ceritinib, brigatinib was associated with longer PFS (ASCEND-1: median 15.7 vs 6.9 months, hazard ratio (HR) [95% confidence interval] = 0.38 [0.26–0.57]; ASCEND-2: median = 18.3 vs 7.2 months, HR = 0.33 [0.20–0.56]) and OS (ASCEND-1: not available; ASCEND-2: median 27.6 vs 14.9 months, HR = 0.33 [0.17–0.63]). Versus alectinib, brigatinib was associated with longer PFS (NP28761: median = 17.6 vs 8.2 months, HR = 0.56 [0.36–0.86]; NP28673: median = 17.6 vs 8.9 months, HR = 0.61 [0.40–0.93]); results for OS were inconclusive (NP28761: median = 27.6 vs 22.7 months, HR = 0.70 [0.42–1.16]; NP28673: median = 27.6 vs 26.0 months, HR = 0.66 [0.39–1.09]). ORR was similar.Conclusion: In crizotinib-refractory ALK + NSCLC patients, relative efficacy estimates suggest brigatinib may have prolonged PFS and OS vs ceritinib and prolonged PFS vs alectinib.Trial registration: ClinicalTrials.gov identifier: NCT02094573.Trial registration: ClinicalTrials.gov identifier: NCT01283516.Trial registration: ClinicalTrials.gov identifier: NCT01685060.Trial registration: ClinicalTrials.gov identifier: NCT01871805.Trial registration: ClinicalTrials.gov identifier: NCT01801111." @default.
• W2894989588 created "2018-10-12" @default.
• W2894989588 creator A5013551992 @default.
• W2894989588 creator A5014132939 @default.
• W2894989588 creator A5027970978 @default.
• W2894989588 creator A5037766242 @default.
• W2894989588 creator A5043983803 @default.
• W2894989588 creator A5051283101 @default.
• W2894989588 creator A5057512367 @default.
• W2894989588 creator A5060404340 @default.
• W2894989588 creator A5068880684 @default.
• W2894989588 date "2018-10-05" @default.
• W2894989588 modified "2023-09-24" @default.
• W2894989588 title "Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer" @default.
• W2894989588 cites W2002108431 @default.
• W2894989588 cites W2005295931 @default.
• W2894989588 cites W2005947177 @default.
• W2894989588 cites W2011129617 @default.
• W2894989588 cites W2016112560 @default.
• W2894989588 cites W2023758807 @default.
• W2894989588 cites W2037418758 @default.
• W2894989588 cites W2090323980 @default.
• W2894989588 cites W2090767358 @default.
• W2894989588 cites W2092901728 @default.
• W2894989588 cites W2096261897 @default.
• W2894989588 cites W2098007718 @default.
• W2894989588 cites W2099530756 @default.
• W2894989588 cites W2111724182 @default.
• W2894989588 cites W2116478428 @default.
• W2894989588 cites W2150529573 @default.
• W2894989588 cites W2153345506 @default.
• W2894989588 cites W2161650275 @default.
• W2894989588 cites W2205667543 @default.
• W2894989588 cites W2295354328 @default.
• W2894989588 cites W2415409512 @default.
• W2894989588 cites W2569631206 @default.
• W2894989588 cites W2581996620 @default.
• W2894989588 cites W2623725180 @default.
• W2894989588 cites W2624310346 @default.
• W2894989588 cites W2801362524 @default.
• W2894989588 cites W2891080905 @default.
• W2894989588 cites W4234236664 @default.
• W2894989588 doi "https://doi.org/10.1080/03007995.2018.1520696" @default.
• W2894989588 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30286627" @default.
• W2894989588 hasPublicationYear "2018" @default.
• W2894989588 type Work @default.
• W2894989588 sameAs 2894989588 @default.
• W2894989588 citedByCount "14" @default.
• W2894989588 countsByYear W28949895882019 @default.
• W2894989588 countsByYear W28949895882020 @default.
• W2894989588 countsByYear W28949895882021 @default.
• W2894989588 countsByYear W28949895882022 @default.
• W2894989588 countsByYear W28949895882023 @default.
• W2894989588 crossrefType "journal-article" @default.
• W2894989588 hasAuthorship W2894989588A5013551992 @default.
• W2894989588 hasAuthorship W2894989588A5014132939 @default.
• W2894989588 hasAuthorship W2894989588A5027970978 @default.
• W2894989588 hasAuthorship W2894989588A5037766242 @default.
• W2894989588 hasAuthorship W2894989588A5043983803 @default.
• W2894989588 hasAuthorship W2894989588A5051283101 @default.
• W2894989588 hasAuthorship W2894989588A5057512367 @default.
• W2894989588 hasAuthorship W2894989588A5060404340 @default.
• W2894989588 hasAuthorship W2894989588A5068880684 @default.
• W2894989588 hasConcept C117643217 @default.
• W2894989588 hasConcept C126322002 @default.
• W2894989588 hasConcept C143998085 @default.
• W2894989588 hasConcept C207103383 @default.
• W2894989588 hasConcept C2776232967 @default.
• W2894989588 hasConcept C2776256026 @default.
• W2894989588 hasConcept C2779220645 @default.
• W2894989588 hasConcept C2779422266 @default.
• W2894989588 hasConcept C2779750558 @default.
• W2894989588 hasConcept C44249647 @default.
• W2894989588 hasConcept C71924100 @default.
• W2894989588 hasConcept C90924648 @default.
• W2894989588 hasConceptScore W2894989588C117643217 @default.
• W2894989588 hasConceptScore W2894989588C126322002 @default.
• W2894989588 hasConceptScore W2894989588C143998085 @default.
• W2894989588 hasConceptScore W2894989588C207103383 @default.
• W2894989588 hasConceptScore W2894989588C2776232967 @default.
• W2894989588 hasConceptScore W2894989588C2776256026 @default.
• W2894989588 hasConceptScore W2894989588C2779220645 @default.
• W2894989588 hasConceptScore W2894989588C2779422266 @default.
• W2894989588 hasConceptScore W2894989588C2779750558 @default.
• W2894989588 hasConceptScore W2894989588C44249647 @default.
• W2894989588 hasConceptScore W2894989588C71924100 @default.
• W2894989588 hasConceptScore W2894989588C90924648 @default.
• W2894989588 hasIssue "4" @default.
• W2894989588 hasLocation W28949895881 @default.
• W2894989588 hasLocation W28949895882 @default.
• W2894989588 hasOpenAccess W2894989588 @default.
• W2894989588 hasPrimaryLocation W28949895881 @default.
• W2894989588 hasRelatedWork W2148613928 @default.
• W2894989588 hasRelatedWork W2503069423 @default.
• W2894989588 hasRelatedWork W2532503897 @default.
• W2894989588 hasRelatedWork W2764093873 @default.
• W2894989588 hasRelatedWork W2799723181 @default.
• W2894989588 hasRelatedWork W2887042787 @default.

• next